Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Yep that the usual pattern a double bounce
I really don’t get peoples obsession always needing news on a share that’s got the World wanting its services & a share with a proven track record with future contracts undoubtably coming
Always is
ORPH on the way back to the 20’s now
ORPH in the forefront & I guess with Omicron things are already happening today in the background & news of new contracts could break anytime
Imutex’s proprietary peptide modelling platform could have possible uses in identifying a peptide for use in a Coronavirus vaccine by using the successful FLU-v vaccine but swapping out the universal flu peptide with a peptide specific to COVID-19. Open Orphan’s management team is optimistic about the potential to monetise these assets through licensing them to Big Pharma for further development.
I have read that the antibodies work with T cells which can still give immunity after the antibodies can’t be detected anymore
CF recently mentioned about wearables Apple Fitbit etc I think on Proactive interview
great news today this will only increase value as predicted making a billion dollar Co
Has everyone forgot about this massive collaboration with LG Chemical
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce the expansion of its existing multi-target collaboration and development agreement with LG Chem Life Sciences (LG Chem), the life sciences division of the South Korean LG Group, to include new programmes incorporating Avacta's Affimer XTTM serum half-life extension system.
In December 2018, Avacta and LG Chem entered into a multi-target therapeutics development agreement to develop Affimer® therapeutics in several disease areas potentially worth over $300m to Avacta. The companies have today agreed to expand this drug development partnership to include Avacta's Affimer XTTM technology, which can be used to control the time a drug spends in the circulation.
The expansion of the partnership includes an undisclosed additional upfront payment, plus near-term pre-clinical milestones and longer-term clinical development milestones totaling $98.5m for two therapeutics to be developed using the Affimer XT technology. Under the terms of the extended agreement, LG Chem has the exclusive rights to develop and commercialise, on a world-wide basis, Avacta's Affimer PD-L1 inhibitor with Affimer XT serum half-life extension.
The expanded partnership also provides LG Chem with rights to develop and commercialise other Affimer and non-Affimer biotherapeutics combined with Affimer XT half-life extension for a range of indications and Avacta could earn up to $55m in milestone payments for each of these new products.
In addition, under the agreement Avacta will earn royalties on all future Affimer XT product sales by LG Chem.
The expansion of the partnership includes an undisclosed additional upfront payment, plus near-term pre-clinical milestones and longer-term clinical development milestones totaling $98.5m for two therapeutics to be developed using the Affimer XT technology. Under the terms of the extended agreement, LG Chem has the exclusive rights to develop and commercialise, on a world-wide basis, Avacta's Affimer PD-L1 inhibitor with Affimer XT serum half-life extension.
The expanded partnership also provides LG Chem with rights to develop and commercialise other Affimer and non-Affimer biotherapeutics combined with Affimer XT half-life extension for a range of indications and Avacta could earn up to $55m in milestone payments for each of these new products.
In addition, under the agreement Avacta will earn royalties on all future Affimer XT product sales by LG Chem.
Avacta has established drug development partnerships with pharma and biotech, including with Moderna Therapeutics Inc., a deal with LG Chem worth up to $310m, a partnership with ADC Therapeutics to develop Affimer drug conjugates and has established a joint venture in South Korea with Daewoong Pharmaceutical focused on cell and gene therapies incorporating Affimer immune-modulators. Avacta actively seeks to license its proprietary platforms in a range of therapeutic areas.
VJust copied this do you think it’s a true fact?
I just read this & not seen this comment before
Antibodies do fade away after some time.! But memory cells develop which stay in your body forever.!! Next time when u are exposed by same virus these memory cells will generate antibodies rapidly;resulting in vey mild or no symptoms.
Yea music City Norwich